Researchers examined results from 522 patients during the study. Compared to the FDA-approved mSEPT9 blood test, Freenome’s test had a higher sensitivity (41 percent to 22 percent).
Compared to stool-based tests, Freenome’s sensitivity for advanced adenomas outperformed fecal immunochemical testing (24 percent) and was comparable to FIT-DNA testing (42 percent).
The new results supplement previously reported data that showed Freenome’s test detected stage 1 and stage 2 CRC at a sensitivity of 94 percent and a specificity of 94 percent.
More articles on surgery centers:
Ohio health system acquires surgery center for $21M
2 Texas health systems suspend surgeries, others don’t
Stryker’s ASC-focused business: 3 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
